cohort_name,cohort_atlas_name,cohortId,atlasId
metastatic prostate cancer,[RQ36] Newly diagnosed mPCa v2,1306,1306
BMI < 18.5 (WHO underweight),[RQ 36] BMI below 18.5 - WHO underweight,991,991
BMI 18.5 - BMI 24.9 (WHO normal weight),[RQ 36] BMI 18.5 - 24.9 - WHO normal weight,992,992
"BMI 25-29,9 (WHO overweight)",[RQ 36] BMI above 25 - WHO overweight,993,993
BMI => 30 (WHO obesity),[RQ 36] BMI above 30 - WHO obesity,994,994
Charlson comorbidity index = 0,[RQ 36] Charlson Comorbidity Index (cut off 0),985,985
CCI = 1,[RQ 36] Charlson Comorbidity Index (cut off 1),986,986
CCI =>2,[RQ 36] Charlson Comorbidity Index (2 and above),987,987
ECOG performance status = 0 or 1,[RQ36] Performance Status ECOG=0 or 1 at met Dx,995,995
ECOG = 2,[RQ36] Performance Status ECOG=2 at met Dx,996,996
ECOG >2,[RQ36] Performance Status ECOG above 2 at met Dx,997,997
Cardiovascular disease,[RQ36] Cardiovascular disease,1079,1079
Chronic kidney disease,[RQ 36] Chronic Kidney Disease v2,1347,1347
Type 2 diabetes,[PIONEER 3.0] O62_Diabetes mellitius_V2,1000,1000
Liver disease,[RQ36] Abnormal hepatic function_v2,1001,1001
PSA levels at diagnosis <10,[RQ36] PSA below 10 at mets dx FINAL,1348,1348
PSA 10-20,[RQ36] PSA 10-20 at mets dx FINAL,1107,1107
PSA > 20,[RQ36] PSA above 20 at mets dx FINAL,1108,1108
Metastasis to nodes,[RQ36] Metastasis to lymph nodes,1002,1002
Metastasis to bone,[RQ36] Metastasis to bones,1003,1003
Metastatsis to central nervous system,[RQ36] Metastasis to CNV,1004,1004
Metastasis to other visceral,[RQ36] Metastasis to other visceral,1005,1005
Other malignancies,[RQ 36] Other malignancies,989,989
Bone marrow failure,[RQ36] Bone marrow failure,1078,1078
Primary adrenal insufficiency,[RQ36] Primary adrenal insufficiency,1007,1007
Secondary adrenal insufficiency,[RQ36] Secondary adrenal insufficiency,1008,1008
HIV positive,[RQ36] HIV positive,1006,1006
Seizures,[RQ36] Seizures,1109,1109
ARASENS exclusion criteria,[RQ 36] ARASENS exclusion v2,1301,1301
ARCHES exclusion criteria,[RQ 36] ARCHES exclusion criteria v2,1302,1302
CHAARTED exclusion criteria,[RQ 36] CHAARTED exclusion critera v2,1303,1303
ENZAMET exclusion criteria,[RQ 36] ENZAMET exclusion criteria v2,1304,1304
GETUG-AFU 15 exclusion criteria,[RQ 36] GETUG-AFU 15 exclusion v2,1305,1305
HORRAD exclusion criteria,[RQ 36] HORRAD exclusion v2,1307,1307
LATITUDE exclusion criteria,[RQ 36] LATITUDE exclusion criteria v2,1308,1308
SWOG-1216  exclusion criteria,[RQ 36] SWOG-1216 exclusion v2,1309,1309
NCT02058706 exclusion criteria,[RQ 36] NCT02058706 exclusion v2,1310,1310
PEACE-1 exclusion criteria,[RQ 36] PEACE-1 exclusion v2,1311,1311
STAMPEDE exclusion criteria,[RQ 36] STAMPEDE exclusion v2,1312,1312
TITAN exclusion criteria,[RQ 36] TITAN exclusion v2,1313,1313
ECOG above 1,[RQ 36] ECOG above 1 (2),1349,1349
Bone marrow failure,[RQ 36] Bone marrow failure,1350,1350
Liver failure,[RQ 36] Liver failure,1351,1351
Chronic kidney disease,[RQ 36] Chronic kidney disease,1352,1352
Stroke,[RQ 36] Stroke - RCT,1353,1353
CVD from ARASENS,[RQ 36] CVD from ARASENS,1354,1354
Metastasis to CNV,[RQ 36] Metastasis to CNV,1355,1355
Seizures,[RQ 36] Seizures (2),1356,1356
CVD from ARCHES,[RQ 36] CVD from ARCHES,1357,1357
ECOG above 2,[RQ 36] ECOG above 2 (2),1358,1358
Peripheral neuropathy,[RQ 36] Peripheral neuropathy (2),1359,1359
CVD from CHAARTED,[RQ 36] CVD from CHAARTED,1360,1360
CVD from SWOG-1216,[RQ 36] CVD from SWOG-1216,1362,1362
HBV or HCV,[RQ 36] HBV or HCV (2),1363,1363
Adrenal insufficiency from SWOG-1216,[RQ 36] Adrenal insufficiency,1364,1364
CVD from PEACE-1,[RQ 36] CVD from PEACE-1,1365,1365
Hypertension,"[CDS 1324] Hypertension_ALL types, including complications_cond, obs_final",1324,1324
Not eligible for any trial ,Not eligible for any trial v2,1368,1368
Not eligible for any trial excluding HORRAD,[RQ 36] Not eligible for any trial excluding HORRAD,1375,1375
eligible for all trials,eligible for all trials v2,1376,1376
Matches the exclusion criteria of any trial,[RQ 36] Matches the exclusion criteria of any trial,1390,1390
Renal Failure,[RQ 36] Renal failure,1378,1378
Cardiac arrest,[RQ 36] Cardiac arrest,1379,1379
Cardiac arrhythmia,[RQ 36] Cardiac arrhythmia,1380,1380
Coronary artery disease,[RQ 36] Coronary artery disease,1387,1387
Acute coronary syndrome,[RQ 36] Acute coronary syndrome,1386,1386
Unstable angina,[RQ 36] unstable angina,1385,1385
Stage 2 hypertension,[RQ 36] stage 2 hypertension,1384,1384
Malignant hypertension,[RQ36] malignant hypertension,1383,1383
Hypertensive disorder,[RQ 36] hypertensive disorder,1382,1382
Heart failure,[RQ 36] heart failure,1381,1381
Thromboembolism,[RQ 36] Thromboembolism,1388,1388
Arteriosclerosis,[RQ 36]  Arteriosclerosis,1389,1389
mHSPC + treatment from ARASENS,[RQ36] Newly diagnosed mPCa v2 + treatent ARASENS,1461,1461
mHSPC + treatment from ARCHES,[RQ36] Newly diagnosed mPCa v2 + treatment from ARCHES,1462,1462
mHSPC + treatment from CHAARTED,[RQ36] Newly diagnosed mPCa v2 + treatment CHAARTED,1463,1463
mHSPC + treatment from ENZAMET,[RQ36] Newly diagnosed mPCa v2 + treatment from ENZAMET,1464,1464
mHSPC + treatment from HORRAD,[RQ36] Newly diagnosed mPCa v2 + treatment from HORRAD,1465,1465
mHSPC + treatment from LATTITUDE,[RQ36] Newly diagnosed mPCa v2 + treatment from LATITUDE,1466,1466
mHSPC + treatment from NCT02058706 ,[RQ36] Newly diagnosed mPCa v2 + treatment from NCT02058706,1467,1467
mHSPC + treatment from PEACE-1,[RQ36] Newly diagnosed mPCa v2 + treatment PEACE-1,1468,1468
mHSPC + treatment from STAMPEDE,[RQ36] Newly diagnosed mPCa v2 + treatment from STAMPEDE,1469,1469
mHSPC + treatment from TITAN,[RQ36] Newly diagnosed mPCa v2 + treatment from TITAN,1470,1470
ARASENS exclusion criteria + treatment from ARASENS,[RQ 36] ARASENS exclusion v2 + treatment from ARASENS,1471,1471
ARCHES exclusion criteria + treatment from ARCHES,[RQ 36] ARCHES exclusion criteria v2 + treatment from ARCHES,1472,1472
CHAARTED exclusion criteria + treatment from CHAARTED,[RQ 36] CHAARTED exclusion critera v2 + treatment from CHAARTED,1473,1473
ENZAMET exclusion criteria + treatment from ENZAMET,[RQ 36] ENZAMET exclusion criteria v2 + treatment from ENZAMET,1474,1474
GETUG-AFU 15 exclusion criteria + treatment from GETUG-AFU,[RQ 36] GETUG-AFU 15 exclusion v2 + treatment from GETUG-AFU-15,1475,1475
HORRAD exclusion criteria + treatment from HORRAD,[RQ 36] HORRAD exclusion v2 + treatment from HORRAD,1476,1476
LATITUDE exclusion criteria + treatment from LATITUDE,[RQ 36] LATITUDE exclusion criteria v2 + treatment from LATITUDE,1477,1477
NCT02058706 exclusion criteria + treatment from NCT02058706 ,[RQ 36] NCT02058706 exclusion v2 + treatment from NCT02058706,1479,1479
PEACE-1 exclusion criteria + treatment from PEACE-1,[RQ 36] PEACE-1 exclusion v2 + treatment from PEACE-1,1480,1480
STAMPEDE exclusion criteria + treatment from STAMPEDE,[RQ 36] STAMPEDE exclusion v2 + treatment from STAMPEDE,1459,1459
TITAN exclusion criteria + treatment from TITAN,[RQ 36] TITAN exclusion v2 + treatment from TITAN,1481,1481
mHSPC + darolutamide,[RQ36] Newly diagnosed mPCa v2 + Darolutamide,1502,1502
mHSPC + enzalutamide,[RQ36] Newly diagnosed mPCa v2 + Enzalutamide,1503,1503
mHSPC + docetaxel,[RQ36] Newly diagnosed mPCa v2 + Docetaxel,1504,1504
mHSPC + radiotherapy,[RQ36] Newly diagnosed mPCa v2 + Radiotherapy,1505,1505
mHSPC + abiraterone,[RQ36] Newly diagnosed mPCa v2 + Abiraterone,1506,1506
mHSPC + apalutamide,[RQ36] Newly diagnosed mPCa v2 + Apalutamide,1507,1507
ARASENS exclusion criteria + darolutamide,[RQ 36] ARASENS exclusion v2 + darolutamide,1491,1491
ARCHES exclusion criteria + Enzalutamide,[RQ 36] ARCHES exclusion criteria v2 + Enzalutamide,1492,1492
CHAARTED exclusion criteria + Docetaxel,[RQ 36] CHAARTED exclusion critera v2 + Docetaxel,1493,1493
ENZAMET exclusion criteria + enzalutamide,[RQ 36] ENZAMET exclusion criteria v2 + Enzalutamide,1494,1494
GETUG-AFU 15 exclusion criteria + docetaxel,[RQ 36] GETUG-AFU 15 exclusion v2 + Docetaxel,1495,1495
HORRAD exclusion criteria + radiotherapy,[RQ 36] HORRAD exclusion v2 + Radiotherapy,1496,1496
LATITUDE exclusion criteria + abiraterone,[RQ 36] LATITUDE exclusion criteria v2 + Abiraterone,1497,1497
NCT02058706 exclusion criteria + enzalutamide,[RQ 36] NCT02058706 exclusion v2 + Enzalutamide,1498,1498
PEACE-1 exclusion criteria + abiraterone,[RQ 36] PEACE-1 exclusion v2 + Abiraterone,1499,1499
STAMPEDE exclusion criteria + abiraterone,[RQ 36] STAMPEDE exclusion v2 + Abiraterone,1500,1500
TITAN exclusion criteria + apalutamide,[RQ 36] TITAN exclusion v2 + Apalutamide,1501,1501
Not eligible for any trial testing Enzalutamide,[RQ 36] Not eligible for any trial testing Enzalutamide,1508,1508
Not eligible for any trial testing Docetaxel,[RQ 36] Not eligible for any trial testing Docetaxel,1509,1509
Not eligible for any trial testing Abiraterone,[RQ 36] Not eligible for any trial testing Abiraterone,1510,1510
Not eligible for any trial testing Enzalutamide + Enzalutamide,[RQ 36] Not eligible for any trial testing Enzalutamide + Enzalutamide,1511,1511
Not eligible for any trial testing Docetaxel + Docetaxel,[RQ 36] Not eligible for any trial testing Docetaxel + Docetaxel,1512,1512
exclusion from all trials testing abiraterone + abiraterone,[RQ 36] Not eligible for any trial testing Abiraterone + Abiraterone,1513,1513
